Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...

- Secures $3.2m in PIPE Financing - - $50m Term Sheet Obtained for Available Financing under Equity Line of Credit - ...

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis ...